Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2018

Shelley Wood

April 02, 2018

News Conference News ACC 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

Shelley Wood

March 27, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Michael O'Riordan

December 09, 2016

Advertisement

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

Alirocumab Price Slashed in Deal With Express Scripts

TCTMD’s Top 10 Most Popular Stories for March 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content